Bayer Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bill Anderson

Algemeen directeur

€11.8m

Totale compensatie

Percentage CEO-salaris	14.3%
Dienstverband CEO	1.6yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bill Anderson's beloning veranderd ten opzichte van Bayer's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-€880m
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

Compensatie versus markt: De totale vergoeding ($USD 12.43M ) Bill } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Austrian markt ($USD 4.29M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Bill te vergelijken met de prestaties van het bedrijf.

CEO

Bill Anderson (58 yo)

1.6yrs

Tenure

€11,804,104

Compensatie

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Anderson	Chairman of the Management Board & CEO	1.6yrs	€11.80m	geen gegevens
Wolfgang Nickl	CFO & Member of Management Board	6.6yrs	€3.42m	geen gegevens
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	6yrs	€3.43m	geen gegevens
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.8yrs	€3.65m	geen gegevens
Heike Prinz	Chief Talent Officer	1.2yrs	€2.53m	geen gegevens
Julio Triana	Member of Management Board & President of Consumer Health Division	less than a year	geen gegevens	geen gegevens
Sebastian Guth	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Amanda McClerren	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Jost Reinhard	Head of Investor Relations	1.1yrs	geen gegevens	geen gegevens
Thomas Laubert	Head of Law	1.3yrs	geen gegevens	geen gegevens
Michael Preuss	Head of Communications	8.5yrs	geen gegevens	geen gegevens
Bernd-Peter Bier	Head of Group Finance	no data	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BAYN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul M. Achleitner	Member of Supervisory Board	22.6yrs	€225.00k	geen gegevens
Ertharin Cousin	Independent Member of the Supervisory Board	5.1yrs	€270.00k	geen gegevens
Heinz Webers	Employee Representative Member of Supervisory Board	2.6yrs	€205.00k	geen gegevens
Simone Bagel-Trah	Independent Member of Supervisory Board	10.6yrs	€227.00k	geen gegevens
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	geen gegevens	geen gegevens
Lori Schechter	Independent Supervisory Board Member	less than a year	geen gegevens	geen gegevens
Horst Baier	Independent Member of Supervisory Board	4.6yrs	€333.00k	geen gegevens
Heike Hausfeld	Vice Chairwoman of Supervisory Board	7.6yrs	€346.00k	geen gegevens
André van Broich	Member of Supervisory Board	12.6yrs	€271.00k	geen gegevens
Otmar Wiestler	Independent Member of Supervisory Board	10.1yrs	€237.00k	geen gegevens
Norbert Winkeljohann	Independent Chairman of Supervisory Board	6.5yrs	€509.00k	geen gegevens
Gunter Hilken	Chairman of Executive Board - Currenta	no data	geen gegevens	geen gegevens

7.0yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BAYN wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Bayer Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Bayer AG Announces CEO Changes

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

New major risk - Share price stability

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

New minor risk - Share price stability

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

New major risk - Share price stability

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.66 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

First quarter 2023 earnings released: EPS: €2.22 (vs €3.35 in 1Q 2022)

Upcoming dividend of €2.40 per share at 4.0% yield

Full year 2022 earnings released: EPS: €4.22 (vs €1.02 in FY 2021)

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur